💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Lorazepam

CHEMBL580 Phase 4 승인됨 Small molecule
Half-Life
10-20 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
321.2 g/mol
LogP
2.4
Phase
4

A benzodiazepine used to treat anxiety disorders, status epilepticus, insomnia, and agitation, and studied as a sedative in critically ill patients. It enhances GABA activity in the brain, producing calming, sedating, and anticonvulsant effects.

분자량

321.1580 g/mol

LogP

2.40

TPSA

61.70 Ų

리핀스키 5의 법칙

통과

치료 영역

Pancreatic Cancer Bladder Cancer Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

약물 분류

N — N - Nervous System

작용 기전

Intermediate-acting benzodiazepine enhancing GABA-A receptor chloride conductance.

Pharmacokinetics (PK)

Half-Life 10-20 hours

Pharmacodynamics (PD)

기전

Intermediate-acting benzodiazepine enhancing GABA-A receptor chloride conductance.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O

                

                

                
                

                    
InChI

                    
InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H10Cl2N2O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
회전 가능 결합

                        
1

                    

                    
                    
                    

                        
무거운 원자

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
A benzodiazepine used to treat anxiety disorders, status epilepticus, insomnia, and agitation, and studied as a sedative in critically ill patients. It enhances GABA activity in the brain, producing calming, sedating, and anticonvulsant effects.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Intermediate-acting benzodiazepine enhancing GABA-A receptor chloride conductance.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Lorazepam: Half-life: 10-20 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Lorazepam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL580.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3958.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.